Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 90
Filter
2.
Clin Microbiol Infect ; 23(3): 179-187, 2017 Mar.
Article in English | MEDLINE | ID: mdl-27793737

ABSTRACT

OBJECTIVES: In Norway, initial treatment of febrile neutropenia (FN) has traditionally been benzylpenicillin plus an aminoglycoside. Internationally, FN is often treated with a broad-spectrum ß-lactam antibiotic. We aimed to compare these two regimens in a prospective, randomized, trial in patients with lymphoma or leukaemia with an expected period of neutropenia ≥7 days, and a suspected bacterial infection. METHODS: Adult neutropenic patients with lymphoma or leukaemia, and a suspected bacterial infection, were randomized for treatment with benzylpenicillin plus an aminoglycoside or meropenem. The primary endpoint was clinical success, defined as no modification of antibiotics and clinical stability 72 h after randomization. RESULTS: Among 322 randomized patients, 297 proved evaluable for analyses. Fifty-nine per cent (95% CI 51%-66%), (87/148) of the patients given benzylpenicillin plus an aminoglycoside were clinically stable, and had no antibiotic modifications 72 h after randomization, compared with 82% (95% CI 75%-87%), (122/149) of the patients given meropenem (p <0.001). When the antibiotic therapy was stopped, 24% (95% CI 18%-32%), (36/148) of the patients given benzylpenicillin plus an aminoglycoside, compared with 52% (95% CI 44%-60%), (78/149) of the patients given meropenem, had no modifications of their regimens (p <0.001). In the benzylpenicillin plus an aminoglycoside arm, the all-cause fatality within 30 days of randomization was 3.4% (95% CI 1.2%-7.9%), (5/148) of the patients, compared with 0% (95% CI 0.0%-3.0%), (0/149) of the patients in the meropenem arm (p 0.03). CONCLUSION: Clinical success was more common in FN patients randomized to meropenem compared with the patients randomized to benzylpenicillin plus an aminoglycoside. The all-cause fatality was higher among the patients given benzylpenicillin plus an aminoglycoside.


Subject(s)
Aminoglycosides/administration & dosage , Anti-Bacterial Agents/administration & dosage , Bacterial Infections/drug therapy , Leukemia/complications , Lymphoma/complications , Penicillin G/administration & dosage , Thienamycins/administration & dosage , Adolescent , Adult , Aged , Female , Humans , Male , Meropenem , Middle Aged , Mortality , Neutropenia/complications , Norway , Prospective Studies , Treatment Outcome , Young Adult
3.
Acta Oncol ; 55(5): 547-53, 2016 May.
Article in English | MEDLINE | ID: mdl-27123741

ABSTRACT

Background This study examined employment patterns and associated factors in lymphoma survivors treated with high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT) from diagnosis to a follow-up survey at a mean of 10 years after HDT-ASCT. Patients and methods All lymphoma survivors aged ≥18 years at HDT-ASCT in Norway from 1987 to 2008, and alive at the end of 2011 were eligible for this cross-sectional study performed in 2012/2013. Participants completed a mailed questionnaire. Job status was dichotomized as either employed (paid work) or not-employed (disability and retirement pension, on economic support, home-makers, or students). Results The response rate was 78%, and the sample (N = 312) contained 60% men. Mean age at HDT-ASCT was 44.3 and at survey 54.0 years. At diagnosis 85% of survivors were employed, 77% before and 77% after HDT-ASCT, and 58% at follow-up. Forty seven percent of the survivors were employed at all time points. The not-employed group at survey was significantly older and included significantly more females than the employed group. No significant between-group differences were observed for lymphoma-related variables. Fatigue, mental distress and type D personality were significantly higher among those not-employed, while quality of life was significantly lower compared to the employed group. Older age at survey, being female, work ability and presence of type D personality remained significantly related to being not-employed at survey in the multivariable analysis. Conclusions Our findings show that not-employed long-term survivors after HDT-ASCT for lymphoma have more comorbidity, cognitive problems and higher levels of anxiety/depression than employed survivors. These factors should be checked and eventually treated in order to improve work ability.


Subject(s)
Employment/statistics & numerical data , Lymphoma/epidemiology , Survivors/statistics & numerical data , Adult , Age Factors , Aged , Antineoplastic Agents/therapeutic use , Comorbidity , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Lymphoma/therapy , Male , Middle Aged , Norway/epidemiology , Quality of Life , Retrospective Studies , Sex Factors , Stem Cell Transplantation , Surveys and Questionnaires , Survivors/psychology , Transplantation, Autologous , Treatment Outcome , Unemployment/statistics & numerical data
4.
Scand J Immunol ; 74(6): 632-9, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21883353

ABSTRACT

We evaluated inflammatory markers in febrile neutropenic lymphoma patients undergoing high-dose chemotherapy with autologous stem cell support. Based on MASCC scores, our patients had a low risk of serious complications and a perspective of a benign initial clinical course of the febrile neutropenia. We also studied the impact of tobramycin given once versus three times daily on these immune markers. Sixty-one patients participating in a Norwegian multicentre prospective randomized clinical trial, comparing tobramycin once daily versus three times daily, given with penicillin G to febrile neutropenic patients, constituted a clinically homogenous group. Four patients had bacteraemia, all isolates being Gram-positive. Thirty-two patients received tobramycin once daily, and 29 patients received tobramycin three times daily. Blood samples were taken at the onset of febrile neutropenia and 1-2 days later. All samples were frozen at -70 °C and analysed at the end of the clinical trial for C-reactive protein (CRP), procalcitonin (PCT), complement activation products, mannose-binding lectin (MBL) and 17 cytokines. We found a mild proinflammatory response in this series of patients. CRP was non-specifically elevated. Ten patients with decreased MBL levels showed the same mild clinical and proinflammatory response. Patients receiving tobramycin once daily showed a more pronounced proinflammatory response compared with patients receiving tobramycin three times daily. Overall, febrile neutropenic cancer patients with a benign clinical course show a mild proinflammatory immune response.


Subject(s)
Antineoplastic Agents/adverse effects , Lymphoma , Neutropenia/drug therapy , Tobramycin/therapeutic use , Adolescent , Adult , Aged , Antineoplastic Agents/therapeutic use , Cytokines/immunology , Female , Humans , Inflammation/immunology , Inflammation/microbiology , Lymphoma/drug therapy , Male , Middle Aged , Neutropenia/chemically induced , Risk Factors , Tobramycin/administration & dosage , Tobramycin/adverse effects , Young Adult
5.
Bone Marrow Transplant ; 46(1): 44-51, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20436517

ABSTRACT

SCF has been shown to synergize with G-CSF to mobilize CD34(+) PBPCs. In this study we report results from this combination after a phase II trial of 32 patients with malignant lymphoma randomized to receive recombinant methionyl human SCF (ancestim, r-metHuSCF) in combination with recombinant methionyl human G-CSF (filgrastim, r-metHuG-CSF) (experimental arm A) or routine chemotherapy plus filgrastim (conventional arm B). The primary objective was to evaluate the side effects and toxicity during priming and mobilization. The secondary objectives were efficacy by the level of blood-circulating PBPCs, the number of harvest days and the time to three-lineage engraftment after autografting. First, during priming 5 patients had 8 serious events, 4 in each arm. A summary of all adverse events revealed 30 (94%) patients suffering from 132 events of all grading. Second, neutropenia and thrombocytopenia was documented in arm B. Third, 9/14 (64%) patients in arm A reached the target of 5 million CD34(+) cells/kg body weight (bw) compared with 13/15 (87%) in arm B. The results represent the first randomized trial of growth factor plus chemotherapy priming and indicate that a formal phase III trial very unlikely may challenge chemotherapy plus r-metHuG-CSF priming in candidates for high-dose therapy.


Subject(s)
Graft Survival/drug effects , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Mobilization/methods , Lymphoma/therapy , Peripheral Blood Stem Cell Transplantation , Stem Cell Factor/analogs & derivatives , Transplantation Conditioning/methods , Adult , Aged , Antigens, CD34/blood , Drug Therapy, Combination/adverse effects , Female , Filgrastim , Granulocyte Colony-Stimulating Factor/adverse effects , Hematopoietic Stem Cell Mobilization/adverse effects , Humans , Lymphoma/blood , Male , Middle Aged , Neutropenia/chemically induced , Neutropenia/prevention & control , Peripheral Blood Stem Cell Transplantation/adverse effects , Pilot Projects , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Stem Cell Factor/adverse effects , Stem Cell Factor/therapeutic use , Thrombocytopenia/chemically induced , Thrombocytopenia/prevention & control , Transplantation Conditioning/adverse effects , Transplantation, Autologous/adverse effects , Young Adult
6.
Clin Oncol (R Coll Radiol) ; 22(10): 828-36, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20363110

ABSTRACT

AIMS: The purpose of the study was to evaluate the response to palliative radiotherapy in patients with painful spinal metastatic disease (SMD). MATERIALS AND METHODS: Three hundred and fifty-five patients admitted to the Norwegian Radium Hospital for radiotherapy for painful SMD were included in a prospective study and were followed up 2 months later. The Brief Pain Inventory was used to assess pain. Analgesic consumption was recalculated into the daily oral morphine-equivalent dose. The radiotherapy-related response rates were calculated using the criteria of the International Bone Metastases Consensus Group (IBMCG), taking into account the use of concomitant analgesics. The response to radiotherapy was assessed as complete or partial and non-response as stable pain, pain progression or 'other'. RESULTS: Brief Pain Inventory forms were obtained at follow-up from 229 of the 355 patients. Two months after radiotherapy, the median self-reported worst pain decreased significantly, but the median oral morphine-equivalent dose increased from 40 to 60 mg (P<0.001). Forty-three per cent of the patients reported pain relief, but a radiotherapy-related response was found in 37% of the patients. Overall correspondence between the patients' self-reported changes in pain experience and the IBMCG-based response categories was obtained in 63% of the patients. CONCLUSIONS: The radiotherapy-related response rates in our study were lower than those reported previously in patients with bone metastases in general, which possibly indicates the presence of more complex pathophysiological mechanisms of pain in SMD.


Subject(s)
Pain/radiotherapy , Palliative Care/methods , Spinal Neoplasms/radiotherapy , Spinal Neoplasms/secondary , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Pain/drug therapy , Pain/etiology , Pain Measurement , Prognosis , Prospective Studies , Young Adult
7.
Clin Oncol (R Coll Radiol) ; 21(10): 753-9, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19850454

ABSTRACT

AIMS: Spinal metastatic disease (SMD) is a serious complication of cancer. To our knowledge, only one population-based study of metastatic spinal cord compression (MSCC) has been carried out. The purpose of the present study was to describe population-based incidences of SMD that required local treatment, such as radiotherapy, surgery or vertebroplasty, including patients with or without cord compression, and to characterise the neurological status of these patients. MATERIALS AND METHODS: During 18 months, all patients with SMD who received local treatment in the South-Eastern Health Region of Norway (population 2.6 million inhabitants) were identified and their medical records were reviewed. RESULTS: In total, 1002 patients were included; 83% had multiple lesions in the spine; 39% had SMD at the time of the primary cancer diagnosis. At the start of local treatment, 31% had MSCC and 11% were not able to walk. The prevalence of MSCC at the time of cancer diagnosis was 0.36%. The annual incidences per 100,000 inhabitants were 26.0 for SMD and 8.1 for MSCC. CONCLUSION: Population-based incidences of SMD requiring local treatment have been reported for the first time. The prevalence of MSCC at the time of cancer diagnosis was higher than previously reported. A more precise definition of MSCC and more population-based studies are needed to reduce selection bias when comparing different studies.


Subject(s)
Spinal Cord Compression/etiology , Spinal Neoplasms/complications , Spinal Neoplasms/secondary , Adult , Aged , Aged, 80 and over , Female , Humans , Incidence , Male , Middle Aged , Norway , Prevalence , Spinal Cord Compression/epidemiology , Spinal Cord Compression/therapy , Spinal Neoplasms/epidemiology , Spinal Neoplasms/therapy , Young Adult
8.
N Engl J Med ; 359(22): 2313-23, 2008 Nov 27.
Article in English | MEDLINE | ID: mdl-19038878

ABSTRACT

BACKGROUND: The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression signatures correlate with survival after treatment of diffuse large-B-cell lymphoma is unclear. METHODS: We profiled gene expression in pretreatment biopsy specimens from 181 patients with diffuse large-B-cell lymphoma who received CHOP and 233 patients with this disease who received R-CHOP. A multivariate gene-expression-based survival-predictor model derived from a training group was tested in a validation group. RESULTS: A multivariate model created from three gene-expression signatures--termed "germinal-center B-cell," "stromal-1," and "stromal-2"--predicted survival both in patients who received CHOP and patients who received R-CHOP. The prognostically favorable stromal-1 signature reflected extracellular-matrix deposition and histiocytic infiltration. By contrast, the prognostically unfavorable stromal-2 signature reflected tumor blood-vessel density. CONCLUSIONS: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment.


Subject(s)
Gene Expression Profiling , Gene Expression , Lymphoma, Large B-Cell, Diffuse/genetics , Stromal Cells/metabolism , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols , Cyclophosphamide , Disease Progression , Doxorubicin , Extracellular Matrix/genetics , Gene Expression Regulation, Neoplastic , Genes, MHC Class II , Germinal Center , Humans , Immunologic Factors/administration & dosage , Kaplan-Meier Estimate , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/mortality , Lymphoma, Large B-Cell, Diffuse/pathology , Middle Aged , Multivariate Analysis , Neovascularization, Pathologic/genetics , Prednisone , Prognosis , Rituximab , Stromal Cells/pathology , Vincristine
9.
Ann Oncol ; 18(6): 1085-9, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17363838

ABSTRACT

BACKGROUND: Secondary central nervous system (CNS) involvement by aggressive lymphoma is a well-known and dreadful clinical complication. The incidence and risk factors for CNS manifestation were studied in a large cohort of elderly (>60 years) patients with aggressive lymphoma. PATIENTS AND METHODS: In all, 444 previously untreated patients were randomized to receive 3-weekly combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone or cyclophosphamide, mitoxantrone, vincristine and prednisone (CNOP) (doxorubicin substituted by mitoxantrone) chemotherapy with or without filgrastim. Prophylactic intrathecal methotrexate was given to patients with lymphoma involvement of bone marrow, testis and CNS near sites. RESULTS: In all 29 of 444 (6.5%) developed CNS disease after a median observation time of 115 months. CNS was the only site of progression/relapse in 13 patients while part of a systemic disease manifestation in 16 patients. In univariate risk factor analysis, CNS occurrence was associated with extranodal involvement of testis (P = 0.002), advanced clinical stage (P = 0.005) and increased age-adjusted International Prognostic Index score (aaIPI; P = 0.035). In multivariate analysis, initial involvement of testis remained significant and clinical stage was of borderline significance. The median survival time was 2 months after presentation of CNS disease. CONCLUSION: A significant proportion of elderly patients with advanced aggressive lymphoma will develop CNS disease. CNS occurrence is related to testis involvement, advanced clinical stage and high aaIPI and the prognosis is dismal.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Central Nervous System Neoplasms/epidemiology , Lymphoma, Non-Hodgkin/pathology , Aged , Cohort Studies , Cyclophosphamide/administration & dosage , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Humans , Incidence , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/mortality , Male , Neoplasm Staging , Prednisone/administration & dosage , Survival Analysis , Survivors , Time Factors , Vincristine/administration & dosage
10.
Bone Marrow Transplant ; 35(12): 1149-53, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15880133

ABSTRACT

High-dose therapy with autologous blood progenitor cell support is now routinely used for patients with certain malignant lymphomas and multiple myeloma. We performed a prospective cost analysis of the mobilization, harvesting and cryopreservation phases and the high-dose therapy with stem cell reinfusion and hospitalization phases. In total, 40 consecutive patients were studied at four different university hospitals between 1999 and 2001. Data on direct costs were obtained on a daily basis. Data on indirect costs were allocated to the specific patient based on estimates of relevant department costs (ie the service department's costs), and by means of predefined allocation keys. All cost data were calculated at 2001 prices. The mean total costs for the two phases were US$ 32,160 (range US$ 19,092-50,550). The mean total length of hospital stay for two phases was 31 days (range 27-37). A large part of the actual cost in the harvest phase was attributed to stem cell mobilization, including growth factors, harvesting and cryopreservation. In the high-dose chemotherapy phase, the most significant part of the costs was nursing staff. Average total costs were considerably higher than actual DRG-based reimbursement from the government, indicating that the treatment of these patients was heavily subsidized by the basic hospital grants.


Subject(s)
Peripheral Blood Stem Cell Transplantation/economics , Antineoplastic Agents/economics , Costs and Cost Analysis , Cryopreservation/economics , Cytapheresis/economics , Financing, Government , Hematopoietic Stem Cell Mobilization/economics , Hospitalization/economics , Humans , Norway , Prospective Studies , Transplantation, Autologous
11.
Eur J Haematol ; 73(3): 179-82, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15287915

ABSTRACT

OBJECTIVE: To evaluate ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma, in terms of objective response rate (ORR) and peripheral blood stem cell (PBSC) harvest mobilization rate. PATIENT POPULATION: A total of 40 patients were included, with a median age of 57 yr. The major histopathological subgroup was diffuse large B-cell lymphoma (n = 27). The indication for ICE was relapse in 23 patients, primary progressive disease in 11, transformation in four and adjuvant primary chemotherapy in one patient. RESULTS: After three cycles of ICE, the ORR was 59%. Among patients with primary progressive disease, ORR was 36% (four of 11). A PBSC harvest after ICE could be performed in 11 of 20 patients, and was sufficient for stem cell rescue in 10 of 20. The median number of collected CD34+ cells was 3.6 x 10(6) (range 1.4-12.5). In six of 10 patients, an adequate PBSC harvest could be performed with a second mobilization regimen. CONCLUSION: In this patient population, the rate of response to ICE was comparable with other second-line regimens used in aggressive lymphoma. The rate of harvest failure (45%) was disappointingly high, compared with previous reports, possibly because of patient selection or differences in granulocyte-colony stimulating factor (G-CSF) dosage.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma/drug therapy , Adult , Aged , Antigens, CD34 , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/toxicity , Carboplatin/administration & dosage , Disease Progression , Etoposide/administration & dosage , Granulocyte Colony-Stimulating Factor/therapeutic use , Hematopoietic Stem Cell Mobilization/standards , Humans , Ifosfamide/administration & dosage , Leukapheresis/standards , Lymphoma/therapy , Lymphoma, Large B-Cell, Diffuse/drug therapy , Lymphoma, Large B-Cell, Diffuse/therapy , Middle Aged , Peripheral Blood Stem Cell Transplantation , Recurrence , Scandinavian and Nordic Countries , Treatment Outcome
12.
Ann Oncol ; 15(7): 1072-8, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15205201

ABSTRACT

BACKGROUND: Burkitt's/Burkitt-like lymphoma (BL/BLL) are highly aggressive lymphomas mainly affecting children and young adults. We report the results in adolescent and adult patients with the use of three successive regimens. PATIENTS AND METHODS: Forty-nine patients aged 15-70 years admitted to the Norwegian Radium Hospital in the period 1982-2001 with a diagnosis of BL/BLL on histological review and who were given chemotherapy with curative intent are included in this analysis. Up to 1987 patients were given doxorubicin-based chemotherapy supplemented with intravenous and intrathecal methotrexate (MmCHOP). From 1987 to 1994, patients who obtained complete remission upon this regimen were consolidated with high-dose therapy with stem-cell support (MmCHOP + HDT). In 1995 we introduced as frontline therapy the German Berlin-Frankfurt-Munster (BFM) regimen. RESULTS: By intention to treat analyses, the progression-free survival rates for patients who received MmCHOP (n=13), MmCHOP + HDT (n=17) or BFM therapy (n=19) are 30.8%, 70.6% and 73.7%, respectively. In the groups of patients who received either the BFM regimen or MmCHOP + HDT, all patients who obtained complete remission upon induction therapy are continuously disease free. There was no treatment-related death. CONCLUSIONS: BL/BLL in adolescents and adults can successfully be treated with 5-day blocks of intensified chemotherapy such as the BFM regimen or CHOP/methotrexate-based chemotherapy consolidated with high-dose therapy. Using the BFM regimen, continuous remissions are obtained without additional myeloablative chemotherapy.


Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Burkitt Lymphoma/therapy , Doxorubicin/therapeutic use , Methotrexate/therapeutic use , Adolescent , Adult , Aged , Antibiotics, Antineoplastic/administration & dosage , Burkitt Lymphoma/mortality , Cancer Care Facilities/statistics & numerical data , Doxorubicin/administration & dosage , Female , Humans , Male , Methotrexate/administration & dosage , Middle Aged , Neoplasm Staging , Norway , Retrospective Studies , Stem Cell Transplantation , Survival Analysis , Survival Rate , Transplantation, Autologous , Treatment Outcome
13.
Br J Haematol ; 125(5): 605-12, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15147376

ABSTRACT

Previously, we have shown that patients with diffuse large B-cell lymphoma (DLBCL) transplanted with contaminated bone marrow (BM) generally have a poor outcome. Whether this is also the case when peripheral blood progenitor cell (PBPC) grafts are used is not known. Forty-three patients with chemosensitive DLBCL or follicular lymphoma grade 3 (FLgr3) were treated with high-dose therapy (HDT) and autologous stem cell support. Nine patients received purged grafts. Quantitative real-time polymerase chain reaction (QRT-PCR) for either the BCL2/IgH translocation or allele specific oligonucleotide (ASO) QRT-PCR for the immunoglobulin heavy chain (IgH) complementarity-determining region 3 were used. Nine of 25 (36%) PBPC grafts contained tumour cells as tested by QRT-PCR, including two grafts purged by CD34(+) cell enrichment combined with B-cell depletion. The level of contamination of the PBPC/CD34(+) cells ranged from 0 to 8.28%. No relationship could be shown between the total number of tumour cells infused and relapse. Patients receiving PCR-positive or PCR-negative PBPC grafts had similar progression-free survival (PFS) (P = 0.49). However, a significant difference was seen in PFS and overall survival (OS) for the patients given >/=6.1 x 10(6) CD34(+) cells/kg compared with those given <6.1 x 10(6) CD34(+) cells/kg (P = 0.01 and P < 0.05 respectively).


Subject(s)
Antigens, CD34/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation/methods , Lymphoma, B-Cell/therapy , Lymphoma, Follicular/therapy , Lymphoma, Large B-Cell, Diffuse/therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carmustine/administration & dosage , Combined Modality Therapy , Cytarabine/administration & dosage , Disease-Free Survival , Etoposide/administration & dosage , Female , Graft Survival , Hematopoietic Stem Cell Mobilization/methods , Humans , Male , Melphalan/administration & dosage , Middle Aged , Salvage Therapy/methods , Treatment Outcome
14.
Ann Hematol ; 83(7): 414-9, 2004 Jul.
Article in English | MEDLINE | ID: mdl-15085385

ABSTRACT

The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (>10%) low (<60%) expression of Ki-67, and high TP53 protein expression (>75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression.


Subject(s)
Lymphoma, Large B-Cell, Diffuse/mortality , Neoplasm Proteins/analysis , ATP Binding Cassette Transporter, Subfamily B, Member 1/analysis , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers , Bleomycin/administration & dosage , Cohort Studies , Cyclophosphamide/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Humans , Ki-67 Antigen/analysis , Leucovorin/administration & dosage , Life Tables , Lymphoma, Large B-Cell, Diffuse/chemistry , Lymphoma, Large B-Cell, Diffuse/drug therapy , Male , Methotrexate/administration & dosage , Middle Aged , Neoplastic Stem Cells/chemistry , Norway/epidemiology , Prednisone/administration & dosage , Prognosis , Proto-Oncogene Proteins c-bcl-2/analysis , Risk Factors , Survival Analysis , Sweden/epidemiology , Treatment Outcome , Tumor Suppressor Protein p53/analysis , Vincristine/administration & dosage
15.
Ann Oncol ; 13(11): 1786-91, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12419752

ABSTRACT

BACKGROUND: To quantify the long-term risk of second cancers (SCs) up to 30 years after primary treatment for Hodgkin's disease (HD) Material and methods In the period 1968 to 1985, an unselected population of 1024 patients started treatment for HD at the Norwegian Radium Hospital (NRH) and were followed for SC from 1969 through 1998 by The Norwegian Cancer Registry. The median age at diagnosis of HD was 40 years, and the median time at follow-up was 14 years. RESULTS: Of 197 SCs, 14 were acute non-lymphocytic leukemia (ANLL), 31 non-Hodgkin's lymphoma (NHL) and 152 solid cancers. The standardized incidence ratio (SIR) was significantly increased for SCs as a group, and for the subgroups ANLL, NHL, lung cancer, breast cancer, stomach cancer and melanoma. ANLL was related to heavy treatment with chemotherapy (CT) and combined CT and radiotherapy (RT), NHL was not treatment related, and solid tumors were related to radiotherapy only or combined RT and CT. The SIR of ANLL and NHL reached a peak between 5 and 10 years after treatment. Solid and non-solid tumors increased with young age at diagnosis of HD and solid tumors increased with follow-up time up to 28 years CONCLUSION: In a long-term follow-up study of HD patients of all ages, the SIR of solid tumors was high in patients treated at young age and decreased with increasing age. Most solid tumors had started within or at the edge of the irradiated field, and SIR of solid tumors increased even 20-30 years after diagnosis.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Hodgkin Disease/therapy , Neoplasms, Second Primary/epidemiology , Adolescent , Adult , Age Distribution , Aged , Cohort Studies , Combined Modality Therapy , Confidence Intervals , Female , Follow-Up Studies , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Humans , Incidence , Male , Middle Aged , Neoplasms, Second Primary/pathology , Neoplasms, Second Primary/therapy , Norway/epidemiology , Probability , Radiotherapy Dosage , Radiotherapy, Adjuvant/methods , Retrospective Studies , Risk Assessment , Risk Factors , Sex Distribution , Survival Analysis , Treatment Outcome
16.
Ann Oncol ; 13(7): 1099-107, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12176790

ABSTRACT

BACKGROUND: To determine the incidence and risk factors for central nervous system (CNS) relapse in patients with non-Hodgkin's lymphoma (NHL). PATIENTS AND METHODS: Patient records were registered prospectively in successive patients with NHL admitted to the Norwegian Radium Hospital from 1980 to 1996. A total of 2514 patients had no CNS involvement at diagnosis and were treated according to standard protocols. The incidence and risk factors for CNS progression or relapse were examined retrospectively. RESULTS: In low-grade (L)-NHL, the risk of CNS involvement was low (2.8%). In high-grade (H)-NHL, lymphoblastic and Burkitt's NHL patients had a high risk of CNS recurrence (24.4%) at 5 years, and prophylaxis seemed to reduce this risk. For the other patients with H-NHL, the proportion with CNS involvement at 5 years was 5.2%. Multivariate analysis identified five independent risk factors, each present in >5% of patients: elevated serum lactate dehydrogenase, serum albumin <35 g/l, <60 years of age, retroperitoneal lymph node involvement and involvement of more than one extranodal site. If four or five of these risk factors were present, the risk of CNS recurrence was in excess of 25% at 5 years. CONCLUSIONS: The risk of CNS involvement in this study is comparable with the results from other large series. CNS prophylaxis is not recommended in any subgroup of L-NHL. The risk of CNS involvement among patients with either Burkitt's or lymphoblastic lymphomas is considerable and these patients should therefore receive intensive chemotherapy including systemic and intrathecal methotrexate. Patients with other types of H-NHL should receive adequate CNS prophylaxis if at least four of the five risk factors identified are present.


Subject(s)
Central Nervous System Neoplasms/diagnosis , Central Nervous System Neoplasms/epidemiology , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, Non-Hodgkin/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biopsy, Needle , Comorbidity , Female , Humans , Incidence , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Neoplasm Staging , Norway/epidemiology , Probability , Proportional Hazards Models , Registries , Retrospective Studies , Risk Factors , Sex Distribution , Survival Analysis
17.
Bone Marrow Transplant ; 28(7): 681-7, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11704791

ABSTRACT

The aim of this study was to investigate the late effects of ABMT on the immune system with regard to protective humoral immunity against common antigens and responses to recall antigens (vaccines). The vaccines were given according to EBMT guidelines from 1995. The protocol included 35 patients with malignant lymphoma in CR 4-10 years after ABMT, and 35 controls. The results show that prior to ABMT the proportion of patients with protective immunity against poliomyelitis, tetanus and diphtheria was similar to that of controls. At study entry 4-10 years after ABMT, the proportion of patients with protective immunity against poliomyelitis and diphtheria was reduced, while all patients maintained protection against tetanus. A significant decrease in geometric mean antibody concentrations or titres was observed against all three antigens during this period. Serum levels of antibodies against different pneumococcal serotypes were lower in the patients than in the controls prior to vaccination. The responses to pneumococcal vaccination, which is considered to be a T cell-independent vaccine, were studied. Unlike controls, a minority of patients achieved protective levels of antibodies after a single vaccination. Despite persistent levels of protective antibodies in many patients post ABMT, secondary booster responses after one vaccination with T cell-dependent vaccines (tetanus, diphtheria and polio) were absent. In conclusion, this study shows that post ABMT, a full re-vaccination program was necessary to mount responses comparable to those observed after a single vaccination in controls.


Subject(s)
Antibodies, Bacterial/biosynthesis , Antibodies, Viral/biosynthesis , Antibody Formation , Antigens, Bacterial/immunology , Antigens, Viral/immunology , Bone Marrow Transplantation , Diphtheria-Tetanus Vaccine/immunology , Immunization, Secondary , Lymphoma/therapy , Pneumococcal Vaccines/immunology , Poliovirus Vaccines/immunology , Adolescent , Adult , Antibodies, Bacterial/immunology , Antibodies, Viral/immunology , Corynebacterium diphtheriae/immunology , Female , Humans , Hypersensitivity, Delayed/immunology , Immunization Schedule , Immunocompetence , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Immunoglobulin G/immunology , Immunologic Memory , Lymphoma/immunology , Male , Middle Aged , Poliovirus/immunology , Practice Guidelines as Topic , Serotyping , Streptococcus pneumoniae/classification , Streptococcus pneumoniae/immunology , Time Factors , Transplantation, Autologous , Tuberculin Test
18.
Tidsskr Nor Laegeforen ; 121(18): 2179-82, 2001 Aug 10.
Article in Norwegian | MEDLINE | ID: mdl-11571996

ABSTRACT

BACKGROUND: During the first decade of 2000, significant increase of radiotherapy capacity in Norway will take place, as the number of linear accelerators will increase from 24 to 36. In Norway, radiotherapy departments are traditionally located only in university hospitals. However, six of the new accelerators will not be installed in existing radiotherapy centres, but in small, new radiotherapy units, set up in selected county hospitals and organized as satellites of the university hospitals, in order to secure the treatment quality. The university hospital is responsible for both medical and technical standards in the satellite, while the county hospitals have the financial responsibility. RESULTS: The satellite model combines two important aspects of hospital management; treatment is geographically decentralized, while treatment quality is centralized. The first radiotherapy satellite was established in the town of Kristiansand in January 2001. We report our experience with this new concept in radiotherapy. INTERPRETATION: The satellite model should be evaluated also for other medical specialties within the university hospitals.


Subject(s)
Health Planning , Hospitals, County/organization & administration , Hospitals, Satellite/organization & administration , Hospitals, University/organization & administration , Nuclear Medicine Department, Hospital/organization & administration , Particle Accelerators/supply & distribution , Radiation Oncology/instrumentation , Hospitals, County/standards , Hospitals, University/standards , Humans , Models, Organizational , Neoplasms/radiotherapy , Norway , Nuclear Medicine Department, Hospital/standards , Radiation Oncology/organization & administration , Workforce
19.
Eur J Haematol Suppl ; 64: 14-20, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11486395

ABSTRACT

In this study we explored whether a standard chemotherapy regimen consisting of mitoguazone, ifosfamide, methotrexate and etoposide (MIME) combined with 5 micrograms/kg or 10 micrograms/kg G-CSF was capable of mobilizing peripheral blood progenitor cells (PBPC) in lymphoma patients. Thirty-three patients with Hodgkin's disease (HD) and 108 patients with non-Hodgkin's lymphoma (NHL) were mobilized with MIME/G-CSF. Most patients were heavily treated with different chemotherapy regimens receiving a median of 11 cycles (range 3-40) of chemotherapy prior to mobilization. Eight of 141 patients failed to mobilize PBPC and bone marrow was harvested. In addition, 10 patients obtained a harvest of < 2.0 x 10(6) CD34+ cells/kg. More than 2.0 x 10(6) CD34+ cells/kg were achieved in all HD patients and in 83% of the NHL patients. Fifty-eight per cent of the patients harvested > or = 5 x 10(6) CD34+ cells/kg. Eleven per cent of the patients developed neutropenic fever during the mobilization and 3% had nadir platelet values below 20 x 10(9)/L. An inverse correlation was observed in high-grade NHL (H-NHL) patients between the number of chemotherapy cycles given before mobilization and yield of CD34+ cells. Such an association was not seen among patients with HD, transformed and low-grade NHL. When G-CSF 10 micrograms/kg was used in combination with MIME, this correlation was no longer seen in patients with H-NHL. There was also association between CD34+ cell yield and prior radiotherapy in patients with HD or transformed NHL or low-grade NHL. These results demonstrate that an ordinary salvage chemotherapy regimen, such as MIME combined with G-CSF, can be successfully used to mobilize PBPC. Although no significant effect of increased dose of G-CSF was found, our data suggest that MIME/G-CSF 10 micrograms/kg should preferentially be used to mobilize PBPC in H-NHL patients pre-treated with > or = 12 cycles of chemotherapy, in irradiated HD patients and in all low-grade and transformed lymphomas.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Granulocyte Colony-Stimulating Factor/administration & dosage , Hematopoietic Stem Cell Mobilization/methods , Lymphoma/drug therapy , Premedication , Adolescent , Adult , Antigens, CD34/analysis , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Blood Component Removal/methods , Blood Component Removal/standards , Etoposide/administration & dosage , Graft Survival , Hematopoietic Stem Cell Mobilization/standards , Hematopoietic Stem Cell Transplantation , Humans , Ifosfamide/administration & dosage , Methotrexate/administration & dosage , Middle Aged , Mitoguazone/administration & dosage , Recurrence , Transplantation, Autologous
20.
J Clin Oncol ; 19(11): 2927-36, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11387366

ABSTRACT

PURPOSE: To determine whether a combination of high-dose therapy and autologous stem-cell transplantation (ASCT) is superior to conventional-dose consolidation and maintenance chemotherapy as postremission therapy in adults with lymphoblastic lymphoma. PATIENTS AND METHODS: One hundred nineteen patients were entered onto this prospective randomized trial from 37 centers. Patients received standard remission induction therapy, and responding patients were randomized either to continue with a conventional consolidation/maintenance protocol (CC) or to receive high-dose therapy and ASCT. In some centers, patients with HLA-identical sibling donors were registered on the trial but proceeded to allogeneic bone marrow transplantation (BMT) without randomization. RESULTS: Of the 119 patients entered, 111 were assessable for response to induction therapy. The overall response rate was 82% (56% complete response, 26% partial response). Of the 98 patients eligible for randomization, 65 were randomized, 31 to ASCT and 34 to CC. Reasons for failure to randomize included patient refusal (12 patients), early progression or death on induction therapy (eight patients), excessive toxicity of induction regimen (six patients), and elective allogeneic BMT (12 patients). With a median follow-up of 37 months, the actuarial 3-year relapse-free survival rate is 24% for the CC arm and 55% for the ASCT arm (hazards ratio = 0.55 in favor of the ASCT arm; 95% confidence interval [CI], 0.29 to 1.04; P =.065). The corresponding figures for overall survival are 45% and 56%, respectively (hazards ratio = 0.87 in favor of the ASCT arm; 95% CI, 0.42 to 1.81; P =.71). CONCLUSION: The use of ASCT in adults with lymphoblastic lymphoma in first remission produced a trend for improved relapse-free survival but did not improve overall survival compared with conventional-dose therapy in this small randomized trial.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Adult , Aged , Bone Marrow Transplantation , Disease-Free Survival , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prospective Studies , Transplantation, Autologous , Transplantation, Homologous , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...